I started my training in medical microbiology (infectious diseases) at the Louisiana State University (LSU) Medical Center in 1992. After completing my degree at LSU, I worked for 12 years in the veterinary vaccine industry, where I developed vaccines for emerging infectious diseases in animals, including West Nile Virus, equine influenza virus, and canine influenza virus after equine influenza jumped species to dogs. At the Institute for Antiviral Research (IAR) at Utah State University (USU), my research has expanded to include developing animal models of human virus infections for evaluation of experimental therapeutics and vaccines. In 2009, the influenza H1N1 pandemic occurred, and the IAR was part of the NIH pandemic response. In 2014, a new strain of enterovirus D68 emerged that changed from causing a respiratory disease to a polio-like disease in children. We developed models for both respiratory and neurological disease in small animals to evaluate experimental therapies. In 2020, we received NIH funding to develop an animal model for COVID-19. SARS-CoV-2 was the fifth emerging disease that I have worked on since starting graduate school in 1992. In addition to research, I teach microbiology and infectious diseases at the College of Veterinary Medicine and a course in One Health for the MPH program at USU.
I started my training in medical microbiology (infectious diseases) at the Louisiana State University (LSU) Medical Center in 1992. After completing my degree at LSU, I worked for 12 years in the veterinary vaccine industry, where I developed vaccines for emerging infectious diseases in animals, including West Nile Virus, equine influenza virus, and canine influenza virus after equine influenza jumped species to dogs. At the Institute for Antiviral Research (IAR) at Utah State University (USU), my research has expanded to include developing animal models of human virus infections for evaluation of experimental therapeutics and vaccines. In 2009, the influenza H1N1 pandemic occurred, and the IAR was part of the NIH pandemic response. In 2014, a new strain of enterovirus D68 emerged that changed from causing a respiratory disease to a polio-like disease in children. We developed models for both respiratory and neurological disease in small animals to evaluate experimental therapies. In 2020, we received NIH funding to develop an animal model for COVID-19. SARS-CoV-2 was the fifth emerging disease that I have worked on since starting graduate school in 1992. In addition to research, I teach microbiology and infectious diseases at the College of Veterinary Medicine and a course in One Health for the MPH program at USU.